Calcineurin inhibitor-associated oral inflammatory polyps after transplantation

Journal of Oral Pathology & Medicine : Official Publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology
Maha Al-MohayaSook-Bin Woo


Calcineurin inhibitors (cyclosporine and tacrolimus) have been used as the mainstay immunosuppressive therapy for solid organ and hematopoietic cell transplantations (HCT) to prevent allograft rejection and for prophylaxis and treatment of the chronic graft-versus-host disease. Adverse effects of these drugs include nephrotoxicity, hepatotoxicity, neurotoxicity, hypertension and gingival hyperplasia. Association of oral non-gingival soft tissue hyperplasia with calcineurin inhibitor therapy has only recently been recognized and is thought to occur infrequently. We present four cases of oral non-gingival inflammatory fibro-vascular hyperplasias attributed to the use of calcineurin inhibitors following solid organ transplantation and HCT. These lesions interfere with function and must be differentiated from other oral lesions, and therefore should be surgically excised.


Apr 1, 1992·Journal of Oral Pathology & Medicine : Official Publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology·G P SchincagliaL del Senno
Mar 1, 1983·Oral Surgery, Oral Medicine, and Oral Pathology·G P WysockiC R Stiller
Nov 1, 1994·Oral Surgery, Oral Medicine, and Oral Pathology·L LeeL E Rotstein
Mar 27, 1997·The New England Journal of Medicine·R E CurtisJ D Boice
Feb 1, 2000·Journal of Cellular Physiology·M KataokaT Nagata
Sep 27, 2000·Journal of Endocrinological Investigation·P Marchetti, R Navalesi
Jan 24, 2002·Special Care in Dentistry : Official Publication of the American Association of Hospital Dentists, the Academy of Dentistry for the Handicapped, and the American Society for Geriatric Dentistry·M al-ZayerJ A Ship
Mar 17, 2004·Journal of Clinical Periodontology·J S EllisJ M Thomason
Mar 17, 2004·Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics·Abtin TabaeeArlene Markowitz
Sep 10, 2004·Progress in Histochemistry and Cytochemistry·Rita Rezzani
Jul 26, 2005·Critical Reviews in Oncology/hematology·Anna L TaylorJ Andrew Bradley
Sep 26, 2006·Oral Surgery, Oral Medicine, Oral Pathology, Oral Radiology, and Endodontics·Indraneel BhattacharyyaDonald M Cohen

❮ Previous
Next ❯


Jul 1, 2008·Expert Opinion on Drug Discovery·Isabella DerlerChristoph Romanin
Nov 18, 2009·Annales de dermatologie et de vénéréologie·E Adenis-LamarreM Beylot-Barry
Jan 22, 2008·The British Journal of Dermatology·S-B Woo, N Treister
Dec 3, 2014·Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology·Anna Yuan, Sook-Bin Woo
Aug 18, 2012·Blood·Nathaniel TreisterLeslie Lehmann
Jun 9, 2016·Journal of Pediatric Hematology/oncology·Dianna Cheney-Peters, Troy C Lund
May 8, 2008·Pharmacoepidemiology and Drug Safety
Jul 10, 2018·Oral Diseases·Hani MawardiNathaniel Treister
Dec 23, 2020·Pediatric Transplantation·Bárbara Soldatelli BallardinCassius Carvalho Torres-Pereira
Dec 22, 2020·World Journal of Clinical Cases·Atsushi UesugiHiroyuki Harada

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.